Shanghai Heyu Biomedical Technology

Abbisko Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Shanghai, China. The company focuses on the discovery and development of innovative small molecule precision oncology therapies through its proprietary discovery platform. Its lead candidate, pimicotinib (ABSK021), is a potent and selective CSF-1R inhibitor currently in Phase 3 trials for tenosynovial giant cell tumor. Abbisko's extensive pipeline also includes several FGFR inhibitors and programs targeting KRAS and EGFR mutations. The company was listed on the Hong Kong Stock Exchange in 2021 and maintains strategic partnerships with global pharmaceutical leaders like Merck KGaA and Eli Lilly.